Table 1.
Baseline characteristics of Omicron infected patients in two groups.
| AZV+DXM | DXM | x2/t | P value | |
|---|---|---|---|---|
| N | 165 | 44 | ||
| Sex,n(%) | ||||
| Male | 106(64.24) | 25(56.82) | 0.819 | 0.366 |
| Female | 59(35.76) | 19(43.18) | ||
| Age, years | 71.75±1.05 | 72.00±2.38 | 3.797 | 0.053 |
| BMI, kg/m2 | 23.99±1.38 | 23.46±1.67 | 0.009 | 0.924 |
| Smoking, n(%) | 21(12.73) | 7(15.91) | 0.000 | 1 |
| Vaccine status, n(%) | 146 (88.48) | 36 (81.82) | 1.372 | 0.214 |
| Underlying diseases, n(%) | ||||
| Hypertension | 96(58.182) | 31(70.46) | 1.494 | 0.222 |
| Diabetes | 42(25.45) | 14(31.82) | 0.557 | 0.455 |
| Coronary heart disease | 13(7.88) | 10(22.73) | 7.039 | 0.008 |
| Chronic lung disease | 20(12.12) | 5(11.36) | 0.027 | 0.871 |
| Nephropathy | 13(7.88) | 1(2.27) | 1.738 | 0.187 |
| Tumor | 29(17.58) | 9(20.46) | 0.215 | 0.643 |
| Cerebrovascular disease | 16(9.69) | 3(6.82) | 0.395 | 0.530 |
| Laboratory findings | ||||
| Leukocytes,109/L | 6.82±1.52 | 7.65±2.37 | 1.281 | 0.259 |
| Lymphocyte, 109/L | 0.70±0.03 | 0.66±0.07 | 0.326 | 0.569 |
| Hemoglobin,g/L | 123.09±25.61 | 115.86±23.35 | 1.977 | 0.161 |
| Platelet,109/L | 173.51±36.33 | 201.58±33.38 | 1.207 | 0.273 |
| CRP, mg/L | 69.81±20.72 | 59.92±17.57 | 0.719 | 0.011 |
| PCT, ng/mL | 2.25±1.02 | 0.87±0.39 | 1.550 | 0.215 |
| LDH, U/L | 304.14±44.46 | 292.05±40.70 | 0.987 | 0.322 |
| Blood glucose,mmol/L | 7.99±1.40 | 10.17±2.01 | 5.803 | 0.018 |
| Albumin,g/L | 32.24±5.42 | 30.99±6.69 | 0.495 | 0.483 |
| Direct bilirubin,umol/L | 5.20±1.43 | 5.31±1.18 | 0.698 | 0.405 |
| Total bilirubin,umol/L | 12.90±2.77 | 10.09±2.50 | 1.658 | 0.201 |
| AST,U/L | 35.53±9.88 | 32.58±7.21 | 0.533 | 0.129 |
| ALT,U/L | 28.99±1.93 | 35.85±6.99 | 4.441 | 0.037 |
| Urea nitrogen,mmol/L | 12.89±5.71 | 14.57±6.16 | 1.164 | 0.131 |
| Cr, µmol/L | 99.38±27.72 | 107.85±30.56 | 1.215 | 0.119 |
| APTT,s | 33.16±5.76 | 33.12±6.88 | 1.929 | 0.109 |
| D-Dimer, mg/L | 2.12±0.29 | 3.52±1.21 | 7.668 | 0.006 |
| Cardiac troponin,pg/mL | 52.13±22.81 | 59.98±29.92 | 1.722 | 0.122 |
| NT-proBNP,pg/mL | 1298.70±264.98 | 3527.22±1362.77 | 14.734 | <0.001 |
| Respiratory support, n(%) | ||||
| Nasal catheter | 98(59.39) | 27(61.36) | 0.078 | 0.779 |
| Venturi mask | 47(28.48) | 12(27.27) | 0.025 | 0.874 |
| high-flow nasal oxygen | 20(12.12) | 5(11.36) | 0.019 | 0.891 |
| Treatment | ||||
| Duration of AZV therapy, days | 9.16±1.28 | -- | -- | -- |
| Average dose of AVZ (mg/d) | 4.35±0.81 | -- | -- | -- |
| Duration of DXM therapy | 10.37±2.26 | 11.15±2.57 | 1.293 | 0.106 |
| Average dose of DXM (mg/d) | 8.76±2.35 | 9.54±2.42 | 1.061 | 0.111 |
AZV, Azvudine; DXM, dexamethasone; BMI, Body Mass Index; CRP, C reaction protein; PCT, procalcitonin; LDH, lactate dehydrogenase; ALT, glutamic pyruvic transaminase; AST, glutamic oxaloacetic transaminase.